Shandong Sito Bio-technology (300583.SZ): Methylprednisolone obtains European CEP certificate for chemical raw materials.

16:49 25/03/2026

Saito Biotechnology (300583.SZ) announced that its controlling subsidiary, Shandong Sairui Pharmaceuticals Co., Ltd. (referred to as "Sairui Pharmaceuticals"), recently received a Certificate of Suitability of the European Pharmacopoeia (referred to as "CEP certificate") issued by the European Medicines Quality Management Agency (referred to as "EDQM") for the active pharmaceutical ingredient: methylprednisolone.

Shandong Sito Bio-technology (300583.SZ) announced that its controlling subsidiary, Shandong Sito Pharmaceutical Co., Ltd. (referred to as "Sito Pharmaceutical"), recently received a Certificate of Suitability to the European Pharmacopoeia (CEP) for the active pharmaceutical ingredient methylprednisolone issued by the European Directorate for the Quality of Medicines. The announcement states that methylprednisolone is a medium-effect, non-halogenated corticosteroid drug used in the emergency treatment of critical diseases. It can also be used for endocrine disorders, rheumatic diseases, collagen diseases, skin diseases, allergic reactions, ophthalmic diseases, gastrointestinal diseases, blood diseases, leukemia, shock, cerebral edema, multiple neuritis, myelitis, and to prevent vomiting caused by cancer chemotherapy, among other uses.

In 2025, China Taiping (00966) recorded a net profit growth of 220.9% and distributed a dividend of 1.23 Hong Kong dollars per share.

C&D PROPERTY (02156): Tian Meitan is appointed as a non-executive director.

MOODY TECH HLDG(01400) announces a profit, expecting shareholders' net profit for 2025 to be approximately RMB 230 million to RMB 250 million, turning from a loss to profit year-on-year.

In 2025, China Taiping (00966) recorded a net profit growth of 220.9% and distributed a dividend of 1.23 Hong Kong dollars per share.

C&D PROPERTY (02156): Tian Meitan is appointed as a non-executive director.

MOODY TECH HLDG(01400) announces a profit, expecting shareholders' net profit for 2025 to be approximately RMB 230 million to RMB 250 million, turning from a loss to profit year-on-year.